RNAi technology targeting the
FGFR3-TACC3
RNAi
fusion genes
glioblastoma
precision medicine
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
27
11
2020
Statut:
epublish
Résumé
Fusion genes form as a result of abnormal chromosomal rearrangements linking previously separate genes into one transcript. The FGFR3-TACC3 fusion gene (F3-T3) has been shown to drive gliomagenesis in glioblastoma (GBM), a cancer that is notoriously resistant to therapy. However, successful targeting of F3-T3 via small molecular inhibitors has not revealed robust therapeutic responses, and specific targeting of F3-T3 has not been achieved heretofore. Here, we demonstrate that depleting F3-T3 using custom siRNA to the fusion breakpoint junction results in successful inhibition of F3-T3+ GBMs, and that exosomes can successfully deliver these siRNAs. We engineered 10 unique siRNAs (iF3T3) that specifically spanned the most common F3-T3 breakpoint with varying degrees of overlap, and assayed depletion by qPCR and immunoblotting. Cell viability assays were performed. Mesenchymal stem cell-derived exosomes (UC-MSC) were electroporated with iF3T3, added to cells, and F3-T3 depletion measured by qPCR. We verified that depleting F3-T3 using shRNA to FGFR3 resulted in decreased cell viability and improved survival in glioma-bearing mice. We then demonstrated that 7/10 iF3T3 depleted F3-T3, and importantly, did not affect levels of wild-type (WT) FGFR3 or TACC3. iF3T3 decreased cell viability in both F3T3+ GBM and bladder cancer cell lines. UC-MSC exosomes successfully delivered iF3T3 in vitro, resulting in F3-T3 depletion. Targeting F3-T3 using siRNAs specific to the fusion breakpoint is capable of eradicating F3T3+ cancers without toxicity related to inhibition of WT FGFR3 or TACC3, and UC-MSC exosomes may be a plausible vehicle to deliver iF3T3.
Sections du résumé
BACKGROUND
BACKGROUND
Fusion genes form as a result of abnormal chromosomal rearrangements linking previously separate genes into one transcript. The FGFR3-TACC3 fusion gene (F3-T3) has been shown to drive gliomagenesis in glioblastoma (GBM), a cancer that is notoriously resistant to therapy. However, successful targeting of F3-T3 via small molecular inhibitors has not revealed robust therapeutic responses, and specific targeting of F3-T3 has not been achieved heretofore. Here, we demonstrate that depleting F3-T3 using custom siRNA to the fusion breakpoint junction results in successful inhibition of F3-T3+ GBMs, and that exosomes can successfully deliver these siRNAs.
METHODS
METHODS
We engineered 10 unique siRNAs (iF3T3) that specifically spanned the most common F3-T3 breakpoint with varying degrees of overlap, and assayed depletion by qPCR and immunoblotting. Cell viability assays were performed. Mesenchymal stem cell-derived exosomes (UC-MSC) were electroporated with iF3T3, added to cells, and F3-T3 depletion measured by qPCR.
RESULTS
RESULTS
We verified that depleting F3-T3 using shRNA to FGFR3 resulted in decreased cell viability and improved survival in glioma-bearing mice. We then demonstrated that 7/10 iF3T3 depleted F3-T3, and importantly, did not affect levels of wild-type (WT) FGFR3 or TACC3. iF3T3 decreased cell viability in both F3T3+ GBM and bladder cancer cell lines. UC-MSC exosomes successfully delivered iF3T3 in vitro, resulting in F3-T3 depletion.
CONCLUSION
CONCLUSIONS
Targeting F3-T3 using siRNAs specific to the fusion breakpoint is capable of eradicating F3T3+ cancers without toxicity related to inhibition of WT FGFR3 or TACC3, and UC-MSC exosomes may be a plausible vehicle to deliver iF3T3.
Identifiants
pubmed: 33241214
doi: 10.1093/noajnl/vdaa132
pii: vdaa132
pmc: PMC7680176
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa132Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
J Neurooncol. 2017 Oct;135(1):183-192
pubmed: 28730289
Cancer Res. 2013 Apr 1;73(7):2333-44
pubmed: 23365134
J Neurooncol. 2019 Sep;144(2):359-368
pubmed: 31292802
Cancer Res. 1986 Dec;46(12 Pt 1):6019-23
pubmed: 3536075
Cancer Res. 2005 Apr 15;65(8):3307-18
pubmed: 15833864
N Engl J Med. 2014 Jun 26;370(26):2537-9
pubmed: 24963575
Chin J Cancer. 2013 Nov;32(11):594-603
pubmed: 24206917
J Clin Invest. 2013 Feb;123(2):855-65
pubmed: 23298836
J Pathol. 2014 Jan;232(1):4-15
pubmed: 24588013
Eur J Cancer. 2014 Dec;50(18):3145-52
pubmed: 25457633
Lancet Oncol. 2011 Oct;12(11):1004-12
pubmed: 21933749
Nature. 1985 Jun 13-19;315(6020):550-4
pubmed: 2989692
Science. 2012 Sep 7;337(6099):1231-5
pubmed: 22837387
Cancer Res. 2009 Dec 1;69(23):8932-40
pubmed: 19920199
PLoS One. 2015 May 01;10(5):e0125277
pubmed: 25933120
Cancer Lett. 2013 Nov 1;340(2):192-200
pubmed: 23376639
J Pathol. 2013 Jul;230(3):270-6
pubmed: 23661334
Neuro Oncol. 2018 Feb 19;20(3):380-390
pubmed: 29016843
Hum Mol Genet. 2013 Feb 15;22(4):795-803
pubmed: 23175443
Neoplasia. 2011 Aug;13(8):716-25
pubmed: 21847363
Lancet Oncol. 2012 Oct;13(10):1011-9
pubmed: 22954507
Cancer Discov. 2013 Jun;3(6):636-47
pubmed: 23558953
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
Cancer Biol Ther. 2014;15(12):1613-21
pubmed: 25535896
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neurosurgery. 2010 Jan;66(1):144-56; discussion 156-7
pubmed: 20023545
Oncogene. 2015 Sep 10;34(37):4845-54
pubmed: 25500544